HIV topic update: protease inhibitor therapy and oral health care
Authors:
- 1 September 1998
- journal article
- research article
- Published by Wiley in Oral Diseases
- Vol. 4 (3) , 159-163
Abstract
Protease inhibitors have been a major advance in the management of HIV disease and have reduced the frequency and severity of many complications, including some oral lesions. They may also be of value in the management of occupational exposures to the virus. However, they may produce adverse effects including oral symptoms such as paraesthesia, taste disturbances and xerostomia, and may interact with a number of drugs used in oral health care. This article summarises the current situation.Keywords
This publication has 43 references indexed in Scilit:
- Paronychia and Pyogenic Granuloma of the Great Toes in Patients Treated with IndinavirNew England Journal of Medicine, 1998
- Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patientsThe Lancet, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapyThe Lancet, 1998
- HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trialThe Lancet, 1997
- Genotypic-resistance assays and antiretroviral therapyThe Lancet, 1997
- Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitorThe Lancet, 1997
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic MillimeterNew England Journal of Medicine, 1993
- Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive SubjectsThe Journal of Infectious Diseases, 1992